STOK

SEC source: 0001209191-20-040613 · doc4.xml · nonDerivative · entry 2

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.88 to $23.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-040613 · doc4.xml · nonDerivative · entry 1

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,800

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-034731 · doc4.xml · derivative · entry 1

Krainer Adrian R. · CIK 0001780081 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,777

Underlying: Common Stock · 14,777 shares

Expires 2030-06-02

F1 · derivative.exercise_date: The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-20-034732 · doc4.xml · derivative · entry 1

LEVIN ARTHUR A · CIK 0001181556 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,777

Underlying: Common Stock · 14,777 shares

Expires 2030-06-02

F1 · derivative.exercise_date: The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-20-034737 · doc4.xml · derivative · entry 1

TZIANABOS ARTHUR · CIK 0001586226 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,777

Underlying: Common Stock · 14,777 shares

Expires 2030-06-02

F1 · derivative.exercise_date: The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-20-034735 · doc4.xml · derivative · entry 1

Smith Julie · CIK 0001557928 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 29,555

Underlying: Common Stock · 29,555 shares

Expires 2020-06-02

F1 · derivative.exercise_date: The option vests as to 1/12th of the total shares on September 3, 2020, and then 1/12th of the total shares vest quarterly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-034729 · doc4.xml · derivative · entry 1

Harrison Seth Loring · CIK 0001404955 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,777

Underlying: Common Stock · 14,777 shares

Expires 2030-06-02

F1 · derivative.exercise_date: The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

F2 · ownership.direct: Under the reporting person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the reporting person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The reporting person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The reporting person therefore disclaims beneficial ownership of the option and underlying common stock.

SEC source: 0001209191-20-034723 · doc4.xml · derivative · entry 1

Burstein Jennifer · CIK 0001640069 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,777

Underlying: Common Stock · 14,777 shares

Expires 2030-06-02

F1 · derivative.exercise_date: The option shall fully vest on June 3, 2021 or, if earlier, the next annual meeting of the issuer's stockholders, subject to the reporting holder's continued service on such vesting date.

SEC source: 0001209191-20-034101 · doc4.xml · derivative · entry 6

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,765

Underlying: Common Stock · 42,880 shares

Expires 2028-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vested as to 1/48th of the total shares on November 22, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-034101 · doc4.xml · derivative · entry 5

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,946

Underlying: Common Stock · 131,147 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 2, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-034101 · doc4.xml · nonDerivative · entry 4

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 172,662

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-034101 · doc4.xml · nonDerivative · entry 3

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 173,027

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.82 to $27.43 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-034101 · doc4.xml · nonDerivative · entry 2

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 174,027

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-034101 · doc4.xml · nonDerivative · entry 1

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 131,147

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-034096 · doc4.xml · derivative · entry 5

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 71,889

Underlying: Common Stock · 20,000 shares

Expires 2028-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option vested as to 3/48th of the total shares on January 22, 2019, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-034096 · doc4.xml · nonDerivative · entry 4

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F4 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.55 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-034096 · doc4.xml · nonDerivative · entry 3

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 14,730

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.39 to $27.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-034096 · doc4.xml · nonDerivative · entry 2

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,605

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.39 to $26.36 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-034096 · doc4.xml · nonDerivative · entry 1

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 33,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-034091 · doc4.xml · derivative · entry 4

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 228,711

Underlying: Common Stock · 2,107 shares

Expires 2018-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date.

SEC source: 0001209191-20-034091 · doc4.xml · nonDerivative · entry 3

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.40 to $27.55 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-034091 · doc4.xml · nonDerivative · entry 2

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 500

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.39 to $27.38 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-034091 · doc4.xml · nonDerivative · entry 1

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 2,107

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-032149 · doc4.xml · derivative · entry 3

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 134,066

Underlying: Common Stock · 7,500 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-032149 · doc4.xml · nonDerivative · entry 2

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

SEC source: 0001209191-20-032149 · doc4.xml · nonDerivative · entry 1

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-024546 · doc4.xml · derivative · entry 4

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,566

Underlying: Common Stock · 7,500 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-024546 · doc4.xml · nonDerivative · entry 2

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 13,500

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-032146 · doc4a.xml · derivative · entry 2

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,566

Underlying: Common Stock · 7,500 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-021319 · doc4.xml · derivative · entry 1

Ticho Barry · CIK 0001780088 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-03-24

F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-021314 · doc4.xml · derivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 197,000

Underlying: Common Stock · 197,000 shares

Expires 2030-03-24

F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-021322 · doc4.xml · derivative · entry 1

Walker Robin A. · CIK 0001790807 · Chief Legal Officer, CCO & Sec

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-03-24

F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-021321 · doc4.xml · derivative · entry 1

Tulipano Stephen J · CIK 0001360548 · CFO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-03-24

F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-021317 · doc4.xml · derivative · entry 1

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,000

Underlying: Common Stock · 42,000 shares

Expires 2030-03-24

F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-021312 · doc4.xml · derivative · entry 1

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2030-03-24

F1 · derivative.exercise_date: The option vests as to 1/48th of the total shares on April 25, 2020 and then 1/48th of the total shares vest monthly thereafter, subject to reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-016360 · doc4.xml · derivative · entry 6

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 230,818

Underlying: Common Stock · 42,779 shares

Expires 2018-12-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The option vests 1/48th of the shares monthly,commencing one month from the date of grant, subject to reporting person's continued service through each vesting date.

SEC source: 0001209191-20-016360 · doc4.xml · derivative · entry 5

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,000

Underlying: Common Stock · 6,324 shares

Expires 2026-02-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: This option vests 1/4th of the shares on the date of grant, with an additional 1/48th (vesting monthly thereafter, subject to reporting person's continued service through each vesting date.

SEC source: 0001209191-20-016360 · doc4.xml · nonDerivative · entry 4

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.14 to $26.61 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-016360 · doc4.xml · nonDerivative · entry 3

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,995

F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.

F2 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.13 to $26.12 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

SEC source: 0001209191-20-016360 · doc4.xml · nonDerivative · entry 2

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 49,103

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-016360 · doc4.xml · nonDerivative · entry 1

Nash Huw M. · CIK 0001780085 · COO & CBO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,324

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-024546 · doc4.xml · derivative · entry 3

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,066

Underlying: Common Stock · 6,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-024546 · doc4.xml · nonDerivative · entry 1

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-032146 · doc4a.xml · derivative · entry 1

Liau Gene · CIK 0001780082 · EVP Research & Preclinical Dev

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,066

Underlying: Common Stock · 6,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on January 16, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-024543 · doc4.xml · derivative · entry 2

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 647,801

Underlying: Common Stock · 50,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001209191-20-024543 · doc4.xml · nonDerivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001209191-20-032142 · doc4a.xml · derivative · entry 1

Kaye Edward M. MD · CIK 0001522780 · Director · CEO

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 647,801

Underlying: Common Stock · 50,000 shares

Expires 2028-04-02

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The option vested as to 1/4th of the total shares on October 17, 2018, and then 1/48th of the total shares vest monthly thereafter, subject to the reporting person's continued service to the issuer through each vesting date.

SEC source: 0001567619-19-021771 · doc1.xml · derivative · entry 1

Walker Robin A. · CIK 0001790807 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 84,800

Underlying: Common Stock · 84,800 shares

Expires 2029-11-14

F1 · derivative.exercise_date: This option shall vest and become exercisable over a 4 year period: 25% of the total shares shall vest on November 12, 2020 and 1/48th of the total shares shall vest and become exercisable on the monthly anniversary thereafter, subject to reporting person's continued service through each vesting date.

SEC source: 0001493152-19-016926 · ownership.xml · nonDerivative · entry 1

RTW INVESTMENTS, LP · CIK 0001493215 · 10% owner

WONG RODERICK · CIK 0001493280 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By RTW

Disclosed balance after: 3,544,248

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein.

SEC source: 0001493152-19-016566 · ownership.xml · nonDerivative · entry 1

RTW INVESTMENTS, LP · CIK 0001493215 · 10% owner

WONG RODERICK · CIK 0001493280 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: Not disclosed

Ownership: Indirect · By RTW

Disclosed balance after: 3,560,682

F2 · price: This transaction was executed in multiple trades at prices ranging from $29.0692 to $29.4345. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the full information regarding the number of shares and prices at which the transaction was effected.

F1 · ownership.nature: The securities reported herein may be deemed beneficially owned by each of: (i) RTW Investments, LP ("RTW"), which is deemed the beneficial owner of shares held by RTW Master Fund, Ltd., RTW Venture Fund Limited and RTW Innovation Master Fund, Ltd. (the "Funds"), which are investment funds managed by RTW, and (ii) Roderick Wong, M.D who serves as the Managing Partner and Chief Investment Officer of RTW. Dr. Wong exercises voting and dispositive control over the securities held by RTW and is therefore deemed to be a beneficial owner of securities owned or controlled by RTW. Each of RTW and Dr. Wong disclaim beneficial ownership of the reported securities held by the Funds, except to the extent of its or his pecuniary interest therein.